Sign In
Buy CALA
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial
10:20am, Monday, 01'st Nov 2021
Calithera Biosciences Inc (NASDAQ: CALA) shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the company's investigational arginase inhibitor, in adults with cystic
Calithera Buys Two Oncology Candidates From Takeda For $45M
06:51am, Tuesday, 19'th Oct 2021
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a to
Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals
04:07pm, Monday, 18'th Oct 2021
-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company's precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer
07:00am, Wednesday, 08'th Sep 2021
KEAPSAKE is a Phase 2 randomized trial evaluating telaglenastat with chemoimmunotherapy in front-line among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2 pathway KEAPSAKE i
Calithera Biosciences to Participate in Two Upcoming Investor Conferences
07:00am, Thursday, 02'nd Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developin
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2021 Results - Earnings Call Transcript
04:39am, Sunday, 08'th Aug 2021
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2021 Results - Earnings Call Transcript
The Upcoming Calithera Cystic Fibrosis Data Could Be Significant
02:05am, Tuesday, 03'rd Aug 2021
The Upcoming Calithera Cystic Fibrosis Data Could Be Significant
SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discoveri
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2021 Results - Earnings Call Transcript
04:31pm, Sunday, 09'th May 2021
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2021 Results - Earnings Call Transcript
Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
07:00am, Friday, 30'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mol
Results from Calithera Biosciences' CANTATA Study to Be Presented at 2021 ASCO Annual Meeting
07:00am, Wednesday, 28'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-mol
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call Transcript
08:19pm, Tuesday, 16'th Mar 2021
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call Transcript
Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights
04:06pm, Tuesday, 16'th Mar 2021
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021-- SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc.
UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021
03:09pm, Friday, 12'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mol
Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021
07:05am, Wednesday, 10'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mol
